PMID- 33123086
OWN - NLM
STAT- MEDLINE
DCOM- 20210526
LR  - 20211204
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 11
DP  - 2020
TI  - Caenorhabditis elegans as a Useful Model for Studying Aging Mutations.
PG  - 554994
LID - 10.3389/fendo.2020.554994 [doi]
LID - 554994
AB  - The Caenorhabditis elegans genome possesses homologs of about two-thirds of all 
      human disease genes. Based on its physiological aging characteristics and 
      superiority, the use of C. elegans as a model system for studies on aging, 
      age-related diseases, mechanisms of longevity, and drug screening has been widely 
      acknowledged in recent decades. Lifespan increasing mutations in C. elegans were 
      found to delay aging by impinging several signaling pathways and related 
      epigenetic modifications, including the insulin/IGF-1 signaling (IIS), 
      AMP-activated protein kinase (AMPK), and mechanistic target of rapamycin (mTOR) 
      pathways. Interestingly, dietary restriction (DR) has been shown to increase the 
      lifespan of numerous metazoans and protect them from multiple age-related 
      pathologies. However, the underlying molecular mechanisms are unclear. In recent 
      decades, C. elegans has been used as a unique model system for high-throughput 
      drug screening. Here, we review C. elegans mutants exhibiting increased in 
      lifespan and age-dependent changes under DR, as well as the utility of C. elegans 
      for drug screening. Thus, we provide evidence for the use of this model organism 
      in research on the prevention of aging.
CI  - Copyright (c) 2020 Zhang, Li, Zhou, Wang and Li.
FAU - Zhang, Siwen
AU  - Zhang S
AD  - Department of Endocrinology and Metabolism, First Affiliated Hospital of Jilin 
      University, Changchun, China.
FAU - Li, Fei
AU  - Li F
AD  - Department of Endocrinology and Metabolism, First Affiliated Hospital of Jilin 
      University, Changchun, China.
FAU - Zhou, Tong
AU  - Zhou T
AD  - Department of Endocrinology and Metabolism, First Affiliated Hospital of Jilin 
      University, Changchun, China.
FAU - Wang, Guixia
AU  - Wang G
AD  - Department of Endocrinology and Metabolism, First Affiliated Hospital of Jilin 
      University, Changchun, China.
FAU - Li, Zhuo
AU  - Li Z
AD  - Department of Endocrinology and Metabolism, First Affiliated Hospital of Jilin 
      University, Changchun, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201005
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
SB  - IM
MH  - AMP-Activated Protein Kinases/physiology
MH  - Aging/*genetics
MH  - Animals
MH  - Caenorhabditis elegans/drug effects/*genetics
MH  - Caloric Restriction
MH  - Drug Evaluation, Preclinical
MH  - Epigenesis, Genetic
MH  - Insulin-Like Growth Factor I/physiology
MH  - Models, Animal
MH  - *Mutation
MH  - Signal Transduction
MH  - TOR Serine-Threonine Kinases/physiology
PMC - PMC7570440
OTO - NOTNLM
OT  - AMPK
OT  - IGF-1
OT  - dietary restriction
OT  - drug screening
OT  - mTOR
EDAT- 2020/10/31 06:00
MHDA- 2021/05/27 06:00
PMCR- 2020/01/01
CRDT- 2020/10/30 05:53
PHST- 2020/04/23 00:00 [received]
PHST- 2020/09/01 00:00 [accepted]
PHST- 2020/10/30 05:53 [entrez]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2021/05/27 06:00 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2020.554994 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2020 Oct 5;11:554994. doi: 
      10.3389/fendo.2020.554994. eCollection 2020.